Observational studyNeurocritical care2026
The Effects of Milrinone Systemic Administration on Cerebral Perfusion as Measured with Computed Tomography in Aneurysmal Subarachnoid Hemorrhage Patients.
Observational study in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAneurysmal subarachnoid hemorrhage (SAH) prognosis is determined by the occurrence of delayed cerebral ischemia (DCI), which is associated with specific dynamics of perfusion computed tomography (CTP) parameters. Systemic administration of milrinone is proposed to reduce DCI, though underlying mechanisms remain putative.
objectiveThis study aimed to describe the effects of milrinone intravenous infusion on systemic and cerebral hemodynamics in patients with SAH.
methodsWe conducted a retrospective observational study including patients diagnosed with aneurysmal SAH and monitored with PiCCO device and CTP. Relationships between milrinone dose, cardiac index (CI), and CTP parameters were assessed.
resultsA total of 17 patients were included, 88% presented cerebral vasospasm, 29% evolved with DCI. CI increased with systemic milrinone dose in the entire population (p < 0.001). Contrarily, cerebral blood flow (CBF) decreased with milrinone in the non-DCI subpopulation (p = 0.002) and was not correlated to it in the DCI one. However, CBF increased with CI in this DCI subpopulation (p = 0.008). Spatial heterogeneity of perfusion, quantified by the global (CoV) and regional (rCoV) coefficients of variation of CBF, decreased with milrinone dose in the non-DCI subpopulation (p < 0.001). While no correlation at the global scale emerged in the DCI subpopulation, rCoV increased with milrinone in DCI regions (p < 0.01).
conclusionsIntravenous infusion of milrinone did not seem to improve cerebral perfusion through systemic effects. In non-DCI patients, milrinone seemed to homogenize CBF and prevent evolution towards DCI. We suggest that in patients with DCI, it failed to do so, such that CBF spatial heterogeneity pathologically increased until infarction. We propose that spatiotemporal evolution of CBF heterogeneity is both a biomarker and a pathophysiological feature of DCI that advocates for further theoretical and experimental exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.